MedWatch

FDA agrees to meeting with Enochian over HIV therapy

The US authority has said yes to a meeting with Enochian Biosciences to discuss a potential start to clinical trials of the company's HIV treatment. The biotech company is also looking to raise funds.

Photo: Andrew Kelly/REUTERS / X02844

Enochian Biosciences has secured a meeting with the US Food and Drug Administration (FDA). This means the company is sticking to its previously announced schedule, which predicted discussions with the authority would start in 2021.

The meeting is a so-called pre-IND meeting, which companies must attend before starting clinical trials in the US. The subject of the meeting is Enochian's HIV therapy, which in the company's own words, could potentially be a "functional cure" for the disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs